Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Virus-like particles (VLPs) are non-infectious nanoscale structures composed of viral proteins. They can be produced in various systems, functioning as delivery carriers of various bio- and nanomaterials. First identified in 1968, these particles self-assemble from viral structural proteins and are efficiently recognized by the immune system. They can be created experimentally using recombinant viral proteins.
Creative Biogene offers a state-of-the-art platform for high-quality VLPs production. Through our proprietary technology, we provide an array of VLPs and continue to innovate new types. Our platform promises efficient and reliable VLPs production, advancing not only current VLPs demand but also the development of novel VLP-based solutions.
Key Features of Our Virus-Like Particles
The applications of VLPs extend to targeted drug delivery. Exploiting their internal cavities, VLPs have been utilized to deliver genes, peptides, proteins, and small drugs. Their enhanced permeability and retention properties make them attractive carriers for delivering treatments and imaging substances, particularly to tumor tissues. Our products can assist you in the development of advanced drug delivery systems, enabling precise and efficient targeting for therapeutic purposes：
Case Study 1
The four dengue serotypes (DENV) are mosquito-borne pathogens linked to severe hemorrhagic disease. The researcher investigated the antigenic landscape of DENV virus-like particles (VLPs) compared to infectious virions, utilizing a diverse panel of well-characterized antibodies. The study revealed that despite the heterogeneity in size, morphology, and maturation state of VLPs, they efficiently displayed highly conformational and quaternary structure-dependent antibody epitopes found on virus particles. Importantly, DENV VLPs demonstrated effectiveness in depleting serotype-specific antibody populations from patient sera. This comprehensive analysis underscores the potential of VLPs as a safe and practical alternative to infectious viruses for both vaccine development and serological diagnostics, offering valuable insights into the epitopic landscape of DENV VLPs.
Figure 1. Researchers expressed DENV1–4 VLPs for characterization, utilizing SDS-PAGE and WB with specific antibodies to analyze protein components. The use of VLPs aids in understanding virus structure. (Metz SW, et al., 2018)
Case Study 2
Mayaro virus (MAYV) is an alphavirus transmitted by mosquitoes, frequently leading to incapacitating rheumatic illness in tropical regions of Central and South America. Researchers utilized the scalable baculovirus-insect cell expression system to generate Mayaro virus-like particles (VLPs) to address the lack of vaccines or antiviral drugs for MAYV disease. Achieving high-level secretion and purification, VLPs from insect cells were compared with those from mammalian cells in terms of immunogenicity using a mouse model. The mammalian cell-derived VLPs induced higher neutralizing antibody titers, offering potent protection against MAYV challenge, including viremia, myositis, tendonitis, and joint inflammation. This research highlights the potential of VLPs as a scalable vaccine strategy for MAYV, contributing to epidemic preparedness against this emerging tropical threat.
Figure 2. Researchers employed insect cells and recombinant baculoviruses for MAYV VLP production to understand the structural features. Utilizing various analytical techniques, including western blotting and transmission electron microscopy, the study assessed the expression, purification, and size distribution of MAYV VLPs. (Abbo SR, et al., 2023)
Q: What are Virus-Like Particles (VLPs)?
A: VLPs are non-infectious nanoscale structures composed of viral proteins. They can self-assemble from viral structural proteins and can function as delivery carriers for various substances such as drugs, vaccines, and imaging agents.
Q: What systems are used for VLPs production and what are the key features?
A: VLPs can be produced in various systems using recombinant viral proteins. The key features include non-infectious and safe formation due to the lack of genetic material, self-assembly from viral structural proteins, and display of diverse viral sources.
Q: What types of research are VLPs used in?
A: VLPs are used in vaccine development, gene therapy, cellular studies, and drug screening. They serve as pivotal tools in these areas due to their ability to mimic virus structure and trigger targeted immune responses.
Q: Are there any special considerations or precautions when dealing with VLPs?
A: As with dealing with any type of biological or viral material, appropriate safety measures and experimental protocols should be followed. Always handle VLPs in a laboratory environment using recommended personal protective equipment (PPE). Since VLPs can be derived from various viruses, it is essential to understand the potential hazards associated with the parent virus and handle the VLPs accordingly.
| Cat.No. | Product Name | Price |
|---|---|---|
| VLP-0001 | Chikungunya Virus-Like Particle | Inquiry |
| VLP-0002 | Dengue Virus-Like Particle (Serotype 1) | Inquiry |
| VLP-0003 | Dengue Virus-Like Particle (Serotype 2) | Inquiry |
| VLP-0004 | Dengue Virus-Like Particle (Serotype 3) | Inquiry |
| VLP-0005 | Dengue Virus-Like Particle (Serotype 4) | Inquiry |
| VLP-0007 | Ebola Virus-Like Particle | Inquiry |
| VLP-0008 | Japanese Encephalitis Virus-Like Particle | Inquiry |
| VLP-0009 | Mayaro Virus-Like Particle | Inquiry |
| VLP-0010 | Norovirus-Like Particle (GI.1) | Inquiry |
| VLP-0011 | Norovirus-Like Particle (GII.4) | Inquiry |
| VLP-0012 | O’nyong’nyong Virus-Like Particle | Inquiry |
| VLP-0013 | Parvovirus VP2 Virus-Like Particle | Inquiry |
| VLP-0014 | Rubella Virus-Like Particle | Inquiry |
| VLP-0015 | Zika Virus-Like Particle | Inquiry |
| VLP-0016 | Wild Type SARS-CoV-2 Virus-Like Particle | Inquiry |
Copyright © Creative Biogene. All rights reserved.